Unlike PRP, which slows disease progression, anti-VEGF treatment can not only slow disease progression but can also improve the Diabetic Retinopathy Severity Scale (DRSS) score, as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS). The gene discussed is VEGFA; the disease is diabetic retinopathy.